PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
29417414-2	2019	Our objective was to develop a SPECT tracer targeting CCR5 for imaging plaque inflammation by radiolabeling D-Ala-peptide T-amide (DAPTA), a CCR5 antagonist, with 111In.	DAPTA	131-136	chemokine (C-C motif) receptor 5	Mus musculus	54-58
29417414-2	2019	Our objective was to develop a SPECT tracer targeting CCR5 for imaging plaque inflammation by radiolabeling D-Ala-peptide T-amide (DAPTA), a CCR5 antagonist, with 111In.	DAPTA	108-129	chemokine (C-C motif) receptor 5	Mus musculus	54-58
29417414-2	2019	Our objective was to develop a SPECT tracer targeting CCR5 for imaging plaque inflammation by radiolabeling D-Ala-peptide T-amide (DAPTA), a CCR5 antagonist, with 111In.	DAPTA	131-136	chemokine (C-C motif) receptor 5	Mus musculus	141-145
29417414-2	2019	Our objective was to develop a SPECT tracer targeting CCR5 for imaging plaque inflammation by radiolabeling D-Ala-peptide T-amide (DAPTA), a CCR5 antagonist, with 111In.	DAPTA	108-129	chemokine (C-C motif) receptor 5	Mus musculus	141-145
29907903-4	2019	The implication of peripheral CCR5 but not CCR1 in CCL4-evoked antinociception was deduced from the inhibition produced by systemic but not intrathecal, administration of the CCR5 antagonist DAPTA, and the inefficacy of the CCR1 antagonist J113863.	DAPTA	191-196	chemokine (C-C motif) receptor 5	Mus musculus	30-34
30658114-0	2019	DAPTA, a C-C chemokine receptor 5 (CCR5) antagonist attenuates immune aberrations by downregulating Th9/Th17 immune responses in BTBR T+ Itpr3tf/J mice.	DAPTA	0-5	chemokine (C-C motif) receptor 5	Mus musculus	9-33
30658114-0	2019	DAPTA, a C-C chemokine receptor 5 (CCR5) antagonist attenuates immune aberrations by downregulating Th9/Th17 immune responses in BTBR T+ Itpr3tf/J mice.	DAPTA	0-5	chemokine (C-C motif) receptor 5	Mus musculus	35-39
30658114-0	2019	DAPTA, a C-C chemokine receptor 5 (CCR5) antagonist attenuates immune aberrations by downregulating Th9/Th17 immune responses in BTBR T+ Itpr3tf/J mice.	DAPTA	0-5	inositol 1,4,5-triphosphate receptor 3	Mus musculus	137-142
30658114-10	2019	Additionally, DAPTA treatment inhibited CCR5+, CD4+CCR5+, CCR5+IL-6+, CCR5+IL-9+, CCR5+IL-17A+, CCR5+RORgammaT+, and upregulated CCR5+IL-10+, and CCR5+Foxp3+ production.	DAPTA	14-19	chemokine (C-C motif) receptor 5	Mus musculus	40-44
30658114-10	2019	Additionally, DAPTA treatment inhibited CCR5+, CD4+CCR5+, CCR5+IL-6+, CCR5+IL-9+, CCR5+IL-17A+, CCR5+RORgammaT+, and upregulated CCR5+IL-10+, and CCR5+Foxp3+ production.	DAPTA	14-19	chemokine (C-C motif) receptor 5	Mus musculus	51-55
30658114-10	2019	Additionally, DAPTA treatment inhibited CCR5+, CD4+CCR5+, CCR5+IL-6+, CCR5+IL-9+, CCR5+IL-17A+, CCR5+RORgammaT+, and upregulated CCR5+IL-10+, and CCR5+Foxp3+ production.	DAPTA	14-19	chemokine (C-C motif) receptor 5	Mus musculus	51-55
30658114-10	2019	Additionally, DAPTA treatment inhibited CCR5+, CD4+CCR5+, CCR5+IL-6+, CCR5+IL-9+, CCR5+IL-17A+, CCR5+RORgammaT+, and upregulated CCR5+IL-10+, and CCR5+Foxp3+ production.	DAPTA	14-19	interleukin 6	Mus musculus	63-67
30658114-10	2019	Additionally, DAPTA treatment inhibited CCR5+, CD4+CCR5+, CCR5+IL-6+, CCR5+IL-9+, CCR5+IL-17A+, CCR5+RORgammaT+, and upregulated CCR5+IL-10+, and CCR5+Foxp3+ production.	DAPTA	14-19	chemokine (C-C motif) receptor 5	Mus musculus	51-55
30658114-10	2019	Additionally, DAPTA treatment inhibited CCR5+, CD4+CCR5+, CCR5+IL-6+, CCR5+IL-9+, CCR5+IL-17A+, CCR5+RORgammaT+, and upregulated CCR5+IL-10+, and CCR5+Foxp3+ production.	DAPTA	14-19	interleukin 9	Mus musculus	75-79
30658114-10	2019	Additionally, DAPTA treatment inhibited CCR5+, CD4+CCR5+, CCR5+IL-6+, CCR5+IL-9+, CCR5+IL-17A+, CCR5+RORgammaT+, and upregulated CCR5+IL-10+, and CCR5+Foxp3+ production.	DAPTA	14-19	chemokine (C-C motif) receptor 5	Mus musculus	51-55
30658114-10	2019	Additionally, DAPTA treatment inhibited CCR5+, CD4+CCR5+, CCR5+IL-6+, CCR5+IL-9+, CCR5+IL-17A+, CCR5+RORgammaT+, and upregulated CCR5+IL-10+, and CCR5+Foxp3+ production.	DAPTA	14-19	interleukin 17A	Mus musculus	87-93
30658114-10	2019	Additionally, DAPTA treatment inhibited CCR5+, CD4+CCR5+, CCR5+IL-6+, CCR5+IL-9+, CCR5+IL-17A+, CCR5+RORgammaT+, and upregulated CCR5+IL-10+, and CCR5+Foxp3+ production.	DAPTA	14-19	chemokine (C-C motif) receptor 5	Mus musculus	51-55
30658114-10	2019	Additionally, DAPTA treatment inhibited CCR5+, CD4+CCR5+, CCR5+IL-6+, CCR5+IL-9+, CCR5+IL-17A+, CCR5+RORgammaT+, and upregulated CCR5+IL-10+, and CCR5+Foxp3+ production.	DAPTA	14-19	chemokine (C-C motif) receptor 5	Mus musculus	51-55
30658114-10	2019	Additionally, DAPTA treatment inhibited CCR5+, CD4+CCR5+, CCR5+IL-6+, CCR5+IL-9+, CCR5+IL-17A+, CCR5+RORgammaT+, and upregulated CCR5+IL-10+, and CCR5+Foxp3+ production.	DAPTA	14-19	interleukin 10	Mus musculus	134-139
30658114-10	2019	Additionally, DAPTA treatment inhibited CCR5+, CD4+CCR5+, CCR5+IL-6+, CCR5+IL-9+, CCR5+IL-17A+, CCR5+RORgammaT+, and upregulated CCR5+IL-10+, and CCR5+Foxp3+ production.	DAPTA	14-19	chemokine (C-C motif) receptor 5	Mus musculus	51-55
30658114-10	2019	Additionally, DAPTA treatment inhibited CCR5+, CD4+CCR5+, CCR5+IL-6+, CCR5+IL-9+, CCR5+IL-17A+, CCR5+RORgammaT+, and upregulated CCR5+IL-10+, and CCR5+Foxp3+ production.	DAPTA	14-19	forkhead box P3	Mus musculus	151-156
30658114-11	2019	We further observed that DAPTA downregulated IL-6, IL-9, IL-17A, and RORgammaT, and increased IL-10 and Foxp3 protein and mRNA expression.	DAPTA	25-30	interleukin 6	Mus musculus	45-49
30658114-11	2019	We further observed that DAPTA downregulated IL-6, IL-9, IL-17A, and RORgammaT, and increased IL-10 and Foxp3 protein and mRNA expression.	DAPTA	25-30	interleukin 9	Mus musculus	51-55
30658114-11	2019	We further observed that DAPTA downregulated IL-6, IL-9, IL-17A, and RORgammaT, and increased IL-10 and Foxp3 protein and mRNA expression.	DAPTA	25-30	interleukin 17A	Mus musculus	57-63
30658114-11	2019	We further observed that DAPTA downregulated IL-6, IL-9, IL-17A, and RORgammaT, and increased IL-10 and Foxp3 protein and mRNA expression.	DAPTA	25-30	interleukin 10	Mus musculus	94-99
30658114-11	2019	We further observed that DAPTA downregulated IL-6, IL-9, IL-17A, and RORgammaT, and increased IL-10 and Foxp3 protein and mRNA expression.	DAPTA	25-30	forkhead box P3	Mus musculus	104-109
29037608-10	2017	Finally, intrathecal CCL8 neutralizing antibody or CCR5 antagonist DAPTA dose-dependently suppressed TNBS-evoked visceral hyperalgesia and spinal ERK activation.	DAPTA	67-72	chemokine (C-C motif) receptor 5	Mus musculus	51-55
29037608-10	2017	Finally, intrathecal CCL8 neutralizing antibody or CCR5 antagonist DAPTA dose-dependently suppressed TNBS-evoked visceral hyperalgesia and spinal ERK activation.	DAPTA	67-72	mitogen-activated protein kinase 1	Mus musculus	146-149
27848062-6	2017	Spinal CCR5 was prominently expressed in microglia, and mechanical allodynia was attenuated by intrathecal injection of DAPTA (a specific antagonist of CCR5) with downregulation of spinal CCR5 and p-PKCgamma expression levels at day 15 in inoculated rats.	DAPTA	120-125	C-C motif chemokine receptor 5	Rattus norvegicus	7-11
28126501-2	2017	Thus, the injection of 3-10ng of CCL5 evoked thermal hyperalgesia through the activation of CCR1 and CCR5 receptors, as demonstrated by the inhibitory effect exerted by the selective antagonists J113863 (0.01-0.1mug) and DAPTA (0.3-3mug), respectively.	DAPTA	221-226	chemokine (C-C motif) ligand 5	Mus musculus	33-37
27848062-6	2017	Spinal CCR5 was prominently expressed in microglia, and mechanical allodynia was attenuated by intrathecal injection of DAPTA (a specific antagonist of CCR5) with downregulation of spinal CCR5 and p-PKCgamma expression levels at day 15 in inoculated rats.	DAPTA	120-125	C-C motif chemokine receptor 5	Rattus norvegicus	152-156
27848062-6	2017	Spinal CCR5 was prominently expressed in microglia, and mechanical allodynia was attenuated by intrathecal injection of DAPTA (a specific antagonist of CCR5) with downregulation of spinal CCR5 and p-PKCgamma expression levels at day 15 in inoculated rats.	DAPTA	120-125	C-C motif chemokine receptor 5	Rattus norvegicus	152-156
27848062-6	2017	Spinal CCR5 was prominently expressed in microglia, and mechanical allodynia was attenuated by intrathecal injection of DAPTA (a specific antagonist of CCR5) with downregulation of spinal CCR5 and p-PKCgamma expression levels at day 15 in inoculated rats.	DAPTA	120-125	protein kinase C, gamma	Rattus norvegicus	199-207
27848062-7	2017	Pre-intrathecal injection of RANTES could reverse the anti-allodynia effects of DAPTA.	DAPTA	80-85	C-C motif chemokine ligand 5	Rattus norvegicus	29-35
26983670-7	2016	RESULTS: Pre-treatment with DAPTA displayed significantly improved neurological functional outcome and reduced cerebral lesion compared with the I/R group animals (p < 0.05); HE staining showed that the I/R group had severe neuronal damage in the ischaemia core and penumbral; Compared with the I/R group, ROCK2 and P-MLC2(Ser19) protein expression in the DAPTA group was reduced (p < 0.05).	DAPTA	28-33	Rho-associated coiled-coil containing protein kinase 2	Rattus norvegicus	309-314
24316469-9	2014	The intraplantar injection of CCL5 (0.5ng) to naive mice evoked thermal hyperalgesia prevented by the coadministration of J113863 or the CCR5 antagonist, d-Ala-peptide T-amide (DAPTA), demonstrating that CCL5 can induce thermal hyperalgesia in mice through the activation of CCR1 or CCR5.	DAPTA	154-175	chemokine (C-C motif) ligand 5	Mus musculus	30-34
24316469-9	2014	The intraplantar injection of CCL5 (0.5ng) to naive mice evoked thermal hyperalgesia prevented by the coadministration of J113863 or the CCR5 antagonist, d-Ala-peptide T-amide (DAPTA), demonstrating that CCL5 can induce thermal hyperalgesia in mice through the activation of CCR1 or CCR5.	DAPTA	154-175	chemokine (C-C motif) receptor 5	Mus musculus	137-141
24316469-9	2014	The intraplantar injection of CCL5 (0.5ng) to naive mice evoked thermal hyperalgesia prevented by the coadministration of J113863 or the CCR5 antagonist, d-Ala-peptide T-amide (DAPTA), demonstrating that CCL5 can induce thermal hyperalgesia in mice through the activation of CCR1 or CCR5.	DAPTA	177-182	chemokine (C-C motif) ligand 5	Mus musculus	30-34
22385043-4	2012	Accordingly, BX513 and D-Ala-peptide T-amide (DAPTA) CCR1 and CCR5 antagonists, respectively, prevented RANTES-induced effect, whereas the CCR3 antagonist SB 328437 was inactive.	DAPTA	46-51	chemokine (C-C motif) receptor 1	Mus musculus	53-57
22528550-10	2012	Administration of CCR5 antagonist, D-ala-peptide T-amide (on days 0, 3 and 6) prevented tactile allodynia and thermal hyperalgesia on days 4 to 14.	DAPTA	35-56	chemokine (C-C motif) receptor 5	Mus musculus	18-22
22385043-4	2012	Accordingly, BX513 and D-Ala-peptide T-amide (DAPTA) CCR1 and CCR5 antagonists, respectively, prevented RANTES-induced effect, whereas the CCR3 antagonist SB 328437 was inactive.	DAPTA	46-51	chemokine (C-C motif) ligand 5	Mus musculus	104-110
18046961-3	2007	D-Ala-peptide T-amide (DAPTA), or Peptide T, named for its high threonine content (ASTTTNYT), is a synthetic peptide comprised of eight amino acids (185-192) of the gp120 V2 region and functions as a viral entry inhibitor by targeting selectively CCR5.	DAPTA	0-21	C-C motif chemokine receptor 5	Homo sapiens	247-251
22033364-2	2012	DAPTA, a HIV gp120-derived CCR5 entry inhibitor, has been shown to inhibit CCR5-mediated monocyte migration and to attenuate neuroinflammation.	DAPTA	0-5	C-C motif chemokine receptor 5	Rattus norvegicus	27-31
22033364-2	2012	DAPTA, a HIV gp120-derived CCR5 entry inhibitor, has been shown to inhibit CCR5-mediated monocyte migration and to attenuate neuroinflammation.	DAPTA	0-5	C-C motif chemokine receptor 5	Rattus norvegicus	75-79
22033364-3	2012	We report here that as a stabilized analog of DAPTA, the short peptide RAP-103 exhibits potent antagonism for both CCR2 (half maximal inhibitory concentration [IC50] 4.2 pM) and CCR5 (IC50 0.18 pM) in monocyte chemotaxis.	DAPTA	46-51	LDL receptor related protein associated protein 1	Rattus norvegicus	71-74
22033364-3	2012	We report here that as a stabilized analog of DAPTA, the short peptide RAP-103 exhibits potent antagonism for both CCR2 (half maximal inhibitory concentration [IC50] 4.2 pM) and CCR5 (IC50 0.18 pM) in monocyte chemotaxis.	DAPTA	46-51	C-C motif chemokine receptor 5	Rattus norvegicus	178-182
19034668-10	2009	The CXCR4 receptor antagonist AMD3100 or the CCR5 receptor inhibitor D-Ala-peptide T-amide blocked HIV IIIB and HIV Bal neurotoxicity, respectively.	DAPTA	69-90	C-C motif chemokine receptor 5	Homo sapiens	45-49
18046961-3	2007	D-Ala-peptide T-amide (DAPTA), or Peptide T, named for its high threonine content (ASTTTNYT), is a synthetic peptide comprised of eight amino acids (185-192) of the gp120 V2 region and functions as a viral entry inhibitor by targeting selectively CCR5.	DAPTA	23-28	C-C motif chemokine receptor 5	Homo sapiens	247-251
16002156-5	2005	We here report that DAPTA potently inhibits specific CD4-dependent binding of gp120 Bal (IC50=0.06 nM) and CM235 (IC50=0.32 nM) to CCR5.	DAPTA	20-25	CD4 molecule	Homo sapiens	53-56
16002156-0	2005	Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA).	DAPTA	81-86	C-C motif chemokine receptor 5	Homo sapiens	0-20
16002156-5	2005	We here report that DAPTA potently inhibits specific CD4-dependent binding of gp120 Bal (IC50=0.06 nM) and CM235 (IC50=0.32 nM) to CCR5.	DAPTA	20-25	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	78-83
16002156-0	2005	Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA).	DAPTA	81-86	C-C motif chemokine receptor 5	Homo sapiens	22-26
16002156-5	2005	We here report that DAPTA potently inhibits specific CD4-dependent binding of gp120 Bal (IC50=0.06 nM) and CM235 (IC50=0.32 nM) to CCR5.	DAPTA	20-25	C-C motif chemokine receptor 5	Homo sapiens	131-135
16002156-6	2005	In co-immunoprecipitation studies, DAPTA (1 nM) blocks formation of the gp120/sCD4 complex with CCR5.	DAPTA	35-40	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	72-77
16002156-6	2005	In co-immunoprecipitation studies, DAPTA (1 nM) blocks formation of the gp120/sCD4 complex with CCR5.	DAPTA	35-40	stearoyl-CoA desaturase 5	Homo sapiens	78-82
16002156-6	2005	In co-immunoprecipitation studies, DAPTA (1 nM) blocks formation of the gp120/sCD4 complex with CCR5.	DAPTA	35-40	C-C motif chemokine receptor 5	Homo sapiens	96-100
16002156-8	2005	The capability of DAPTA to potently block gp120-CD4 binding to the major co-receptor CCR5 explains its molecular and therapeutic mechanism of action as a selective antiviral entry inhibitor for R5 tropic HIV-1 isolates.	DAPTA	18-23	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	42-47
16002156-8	2005	The capability of DAPTA to potently block gp120-CD4 binding to the major co-receptor CCR5 explains its molecular and therapeutic mechanism of action as a selective antiviral entry inhibitor for R5 tropic HIV-1 isolates.	DAPTA	18-23	CD4 molecule	Homo sapiens	48-51
16002156-8	2005	The capability of DAPTA to potently block gp120-CD4 binding to the major co-receptor CCR5 explains its molecular and therapeutic mechanism of action as a selective antiviral entry inhibitor for R5 tropic HIV-1 isolates.	DAPTA	18-23	C-C motif chemokine receptor 5	Homo sapiens	85-89
9465119-5	1998	Furthermore, the putative gp120 antagonist, Peptide T (DAPTA), prevented the suppression of GH by gp120.	DAPTA	55-60	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	26-31
14499289-1	2003	D-Ala-Peptide T-amide (DAPTA), the first viral entry inhibitor, blocks chemokine (CCR5) receptors, not CD4.	DAPTA	23-28	C-C motif chemokine receptor 5	Homo sapiens	82-86
15043212-0	2003	Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors.	DAPTA	10-31	C-C motif chemokine receptor 5	Homo sapiens	77-81
15043212-0	2003	Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors.	DAPTA	33-38	C-C motif chemokine receptor 5	Homo sapiens	77-81
9848397-10	1998	DAPTA inhibited significantly the monocyte and lymphocyte chemotactic activity of RANTES (p < 0.005, < 0.001).	DAPTA	0-5	C-C motif chemokine ligand 5	Homo sapiens	82-88
15979806-6	2005	The current study investigated the ability of D-Ala-peptide T-amide (DAPTA), a chemokine receptor 5 chemokine receptor antagonist of monocyte chemotaxis, to influence the consequences of chronic infusion of lipopolysaccharide.	DAPTA	46-67	C-C motif chemokine receptor 5	Rattus norvegicus	79-99
15979806-6	2005	The current study investigated the ability of D-Ala-peptide T-amide (DAPTA), a chemokine receptor 5 chemokine receptor antagonist of monocyte chemotaxis, to influence the consequences of chronic infusion of lipopolysaccharide.	DAPTA	69-74	C-C motif chemokine receptor 5	Rattus norvegicus	79-99
14499289-1	2003	D-Ala-Peptide T-amide (DAPTA), the first viral entry inhibitor, blocks chemokine (CCR5) receptors, not CD4.	DAPTA	0-21	C-C motif chemokine receptor 5	Homo sapiens	82-86
9465119-5	1998	Furthermore, the putative gp120 antagonist, Peptide T (DAPTA), prevented the suppression of GH by gp120.	DAPTA	55-60	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	98-103
9465119-7	1998	DAPTA prevented the GH suppression by gp120 in both of the pituitary cell paradigms.	DAPTA	0-5	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	38-43